Geode Capital Management LLC Boosts Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Geode Capital Management LLC raised its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,071,761 shares of the company's stock after buying an additional 89,032 shares during the period. Geode Capital Management LLC owned about 0.28% of GoodRx worth $4,986,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. National Bank of Canada FI lifted its position in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after buying an additional 2,151 shares in the last quarter. Versor Investments LP purchased a new stake in shares of GoodRx in the fourth quarter worth $54,000. Verus Capital Partners LLC bought a new stake in shares of GoodRx during the 4th quarter valued at $55,000. Steward Partners Investment Advisory LLC purchased a new position in shares of GoodRx during the 4th quarter valued at $56,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of GoodRx during the fourth quarter worth about $56,000. 63.77% of the stock is owned by institutional investors.

GoodRx Stock Performance

Shares of NASDAQ:GDRX traded up $0.03 during trading on Tuesday, hitting $4.66. The stock had a trading volume of 448,983 shares, compared to its average volume of 1,375,401. The stock has a 50-day simple moving average of $4.57 and a two-hundred day simple moving average of $4.87. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -155.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. GoodRx Holdings, Inc. has a 12-month low of $3.82 and a 12-month high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

Analyst Ratings Changes

GDRX has been the subject of a number of research reports. Truist Financial dropped their price target on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research note on Thursday, April 10th. Citigroup reduced their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research note on Friday, January 10th. Wells Fargo & Company cut their price target on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday. Finally, KeyCorp decreased their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, GoodRx has an average rating of "Moderate Buy" and an average price target of $7.84.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.